Compare WINA & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WINA | SANA |
|---|---|---|
| Founded | 1988 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2006 | 2021 |
| Metric | WINA | SANA |
|---|---|---|
| Price | $418.13 | $2.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 64.6K | ★ 2.4M |
| Earning Date | 04-15-2026 | 03-03-2026 |
| Dividend Yield | ★ 3.23% | N/A |
| EPS Growth | 3.76 | ★ 17.24 |
| EPS | ★ 11.30 | N/A |
| Revenue | ★ $86,055,700.00 | N/A |
| Revenue This Year | $5.55 | N/A |
| Revenue Next Year | $6.03 | N/A |
| P/E Ratio | $37.98 | ★ N/A |
| Revenue Growth | ★ 5.86 | N/A |
| 52 Week Low | $295.79 | $1.27 |
| 52 Week High | $526.81 | $6.55 |
| Indicator | WINA | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 42.46 | 32.39 |
| Support Level | $405.17 | N/A |
| Resistance Level | $451.93 | $3.36 |
| Average True Range (ATR) | 19.63 | 0.19 |
| MACD | -1.60 | -0.01 |
| Stochastic Oscillator | 20.69 | 6.65 |
Winmark Corp is a franchisor of value-oriented retail store concepts that buy, sell, and trade gently used merchandise. The company has one reportable segment including Franchising and one non-reportable segment Leasing. The franchising segment franchises value-oriented retail store that buys, sell, trade, and consign merchandise as well as provide strategic consulting services relating to franchising. The leasing segment includes middle-market equipment leasing business and small-ticket financing business. It generates a majority of its revenue from the Franchising segment.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.